CompletedNCT00218426
Naltrexone implant compared with oral naltrexone for heroin relapse prevention
About this title
Read the official source —Medication studyAges 18–50Russia + United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 50 years.
- Listed locations
- Philadelphia and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateStarted: July 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 306
- Sponsor
- University of Pennsylvania
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States, Russia
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT00218426
- Official title
Show the full official title
Addiction Treatment in Russia: Oral and Depot Naltrexone
Get this study by email
Recruitment & locations
CompletedPhiladelphia, United States · Saint Petersburg, Russia · Russia
Questions about this study
Who is behind this study?
The study sponsor is University of Pennsylvania, a university.
Did this study involve medication?
Yes. The study involved medication, including naltrexone implant, oral naltrexone, oral placebo naltrexone and placebo implant.
Who was this study for?
Listed age limits: 18 years to 50 years.
